Sign up now!
Don't show this again
Sweepstakes Rules

We’re glad you’re enjoying Poultry Health Today.
Access is free but you’ll need to register to view more content.
Already registered? Sign In
Tap to download the app
REPORTSCollect articles and features into your own report to read later, print or share with others

Create a New Report


Read Later

Create a new report

Report title (required) Brief description (optional)
follow us

You must be logged in to edit your profile.

Sponsored by Zoetis

Sponsored By Zoetis

PHTweb AAAP Jackwood 07688 Sr

Poultry experts cite frustration with infectious bronchitis variants

Download Button

Download a free copy of the booklet

New, variant strains of infectious bronchitis virus (IBV) in poultry will continue to emerge, but their control may depend primarily on strategic vaccination protocols that provide cross-protection from available IBV vaccines, panelists indicated at an industry roundtable, “Infectious Bronchitis: Evolving Strategies for an Evolving Virus.”

Mark Jackwood, PhD, a molecular virologist at the University of Georgia known for his IBV expertise, explained that IBV is an RNA coronavirus with a huge genome.

“When it replicates, it’s not very good at copying that genome, so [the virus] has a high mutation rate and it makes mistakes.”

The bottom line, he said, is that anytime IBV replicates, it’s changing. Whether those changes result in a virus that can have a selective advantage and become an economic problem seems to occur about every 5 years, Jackwood said.

‘Best of all worlds’

In his scientific opinion, a homologous vaccine administered properly offers the best of all worlds.

“It absolutely is. The problem we run into is like the one we have with [the relatively new IB variant] Delmarva/1639,” he said. “If we start trying to make a [commercial] vaccine today, it’s going to be probably 3 or 4 years until we have it on the market.

“So, we vaccinate with one or more strains of bronchitis virus to get as much cross-protection as we can. We probably get a lessening of the clinical signs associated with that, and everybody congratulates each other and says we did a great job. But meanwhile, the virus is replicating under the radar until it finally gets to a point where it surfaces again,” Jackwood explained.

Impact on mutation

Asked about the impact of vaccination on the evolution of IBV, Jackwood said it’s probably not fair to make a blanket statement that vaccine pressure will push the virus to evolve and mutate or emerge as a strain that will cause problems.

Although some studies would indicate that vaccines can accelerate the mutation rate of IBV viruses, other studies indicate the virus will replicate and change rapidly in the field without any vaccine pressure.

“If we do a good job of vaccinating like we’re supposed to, I think it actually helps with keeping the virus from replicating as much — and maybe instead of 5 years we can prolong it to 8 years or 10 years. The virus mutates; that’s what this virus does and we can’t change that,” Jackwood said.

‘Complicate the situation’

Guillermo Zavala, DVM, MAM, PhD, of Avian Health International and adjunct professor, University of Georgia, raised the possibility that while essential for effective control, some vaccination programs might contribute to IBV’s evolution.

He noted that poultry producers “can easily complicate the situation” when they are “dealing with an area heavily populated with birds from multiple companies and where eight or nine different vaccine strains are circulating simultaneously all the time.”

A planned strategy is lacking, Zavala indicated. In northeast Georgia, for instance, there are no fewer than eight different vaccine strains used every single day, he reported. Some companies spray vaccines with one, two or even three serotypes at the hatchery. Other companies boost in the field with yet another IBV strain.

“So, what does that actually do to virus evolution?” he asked the panel.

Practically speaking

Meagan Slater, DVM, said before she joined Mountaire Farms, she had experience with five poultry companies that had Delmarva/1639 in multiple polymerase chain reaction sequences. A couple of them experienced serious problems at processing as a result.

“We tried multiple vaccine approaches because of company preferences. Some opted for a generic, multiple-boost protection approach. Others tried both Georgia 08 vaccines. It was kind of a wash across the board. There were breakthroughs [of the virus] on every program, although I think generally people were happy because [the disease became] less of a problem,” she said.

But vaccination can’t do it all, she added.  “Vaccination is going to decrease your clinical signs, but if the pressures in the environment are too high — decreased ventilation and other factors that come along with winter — it’s just not going to hold,” Slater said.

Reflecting on his experience at Sanderson Farms, David French, DVM, offered a practical assessment of managing IBV.

“I think we’d all agree that in a production scenario, we just want the problem [of IBV] to go away. We’ve got an issue, we’ve got mortality and we’re under pressure to fix the immediate problem.

“The choices we have might not include a homologous vaccine but a vaccine that might give us some protection and relief from the clinical signs we’re seeing.”

Editor’s note: This report was adapted from “Infectious Bronchitis: Evolving Strategies for an Evolving Virus,” highlights of a roundtable discussion sponsored by Zoetis. To download a free copy, click here.




Shareicon Pht 1
Share It
New, variant strains of infectious bronchitis virus in poultry will continue to emerge. The question is, how do we control them?

Click an icon to share this information with your industry contacts.

Posted on April 30, 2020

tags: , ,
  • ‘Reverse genetics’ may offer new IBV vaccine targets

    Researchers at The Pirbright Institute in the UK report that a recent study provides evidence that mutations in the genetic code for non-structural proteins “offer a promising way” to make vaccines against infectious bronchitis virus (IBV) safer.

  • Why ‘vaccinated’ chickens still get infected with IBV — and what to do about it

    While many vaccines and vaccination programs effectively protect against the highly contagious infectious bronchitis virus in poultry, outbreaks of the disease still occur in vaccinated flocks.

  • Poultry industry can learn from COVID-19

    Biosecurity is not sufficient to control avian coronaviruses like infectious bronchitis in commercial poultry, no matter how good it is, said Mark Jackwood, PhD, a molecular virologist and professor of avian medicine at the University of Georgia.

  • Poor IBV vaccine performance in broiler study underlines need for surveillance

    A whole-complex study of broiler breeders in Georgia found underwhelming infectious bronchitis vaccine performance – but with better surveillance and protocols, outcomes could be improved.

You must be logged in to edit your profile.

Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.